Notice about cookies

Close

This website uses a limited number of cookies to improve your browsing experience. For further information (including how to withdraw consent), please refer to our Cookie Policy. By clicking Accept below or continuing to use this website (including closing this message), you confirm that you have read and consent to our use of cookies as detailed in our Cookie Policy.

Accept

UCB's Global Corporate Website
Welcome to UCB in the United States

Categories

Archives

Dec

01

UCB to present data at the American Epilepsy Society 76th Annual Meeting 2022 supporting a decades-long commitment to transforming epilepsy care

Read More Share:linkedin| twitter| email

Nov

23

Epilepsia Publishes Interim Results of Open-Label Extension Study of FINTEPLA® (fenfluramine) Oral Solution in Patients with Lennox-Gastaut Syndrome (LGS)

Read More Share:linkedin| twitter| email

Nov

22

UCB Submits Response to FDA Complete Response Letter for Bimekizumab

Read More Share:linkedin| twitter| email

Nov

21

Nicole Williams’ Has an Impact From Investments to Innovation to Inclusion

Read More Share:linkedin| twitter| email

Nov

17

Shaping the Future of Psoriatic Arthritis Care in Rural Settings

Read More Share:linkedin| twitter| email

Nov

14

UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients

Read More Share:linkedin| twitter| email

Nov

11

United for Veterans and our Employees Who Serve

United for Veterans is one of UCB’s Employee Resource Groups (ERGs) focused on veterans and veteran supporters. United for Veterans leverages the combined strength of UCB’s veterans and veteran supporters by encouraging through shared experiences, celebrating veterans’ diversity, inspiring professional development, and honoring veteran communities through servant leadership opportunities while fulfilling our company goals and diversity, equity, and inclusion ambition.

Read More Share:linkedin| twitter| email

Nov

10

Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis

Read More Share:linkedin| twitter| email

Nov

09

Moving the Conversation Forward in Rheumatology – UCB at ACR Convergence 2022

Read More Share:linkedin| twitter| email

Nov

08

UCB Reinforces Commitment to Rheumatology With 15 Abstracts Including New Late-Breaking Data at ACR Convergence 2022

Read More Share:linkedin| twitter| email

© 2009 - 2020 UCB, Inc., Atlanta. All rights reserved.
USPR-CORP-0115-00003(2)